Shaping a new era of global health investment, policy, planning and prevention
AVAC is part of a robust civil society movement helping to shape a new era of global health spending and planning related to HIV prevention. We mobilize to ensure programs, products and policies are evidence-based, inclusive and effective. With our partner network, we identify critical needs and develop strategic campaigns to advance HIV prevention, with a focus on ensuring a rich pipeline of options move through research and development, and rollout effectively to reach the communities who need them most.
Our advocacy takes place:
infographic
Official characterizations of the HIV response as “doing very good” warrant a closer look at the data. AVAC’s analysis of PEPFAR prevention figures shows PrEP initiations declined 41% in one year, with women and men each seeing drops exceeding 50%. Data on key populations remains unavailable.
report
This report highlights AVAC’s role as a trusted voice, a translator of science and catalyst for action and advocacy. It reflects an organization ready for the future: supporting African leadership, strengthening bridges from R&D to delivery and preparing for a new chapter as we move forward into our fourth decade as an organization.
article
AVAC’s formal input submitted on the re-competition of the NIAID HIV/AIDS Clinical Trials Networks. The recommendations were informed by the People’s Research Agenda (PRA), a comprehensive framework developed through consultations with over 130 community representatives across 23 countries.
Percentage of key population-serving implementing partners that have reported full or partial termination of the provision of KP services due to US funding cuts (as of April 2025).
Accelerating the development and delivery of STI prevention.
Using data for smarter advocacy and high-impact campaigns.
Developing an Africa-centered network dedicated to accelerating HIV prevention research, and advancing equitable access to proven HIV prevention products.
Lenacapavir has the potential to reach millions — and the momentum is building. Using the current oral PrEP market as a baseline, this graphic estimates what demand for LEN could look like through 2028 and shows how current donor commitments stack up against that opportunity.
As an advocate for scientific integrity, public health and evidence-based policymaking, AVAC strongly opposes the White House Office of Management and Budget’s proposed Regulation for Federal Financial Assistance. This document outlines AVAC’s key concerns with the proposal, which were submitted July 9, 2026.
In a landmark moment, South Africa today became the 9th African country to introduce lencapavir (LEN) for HIV prevention. South Africa’s introduction of LEN is especially significant given the country’s central role in shaping the regional HIV response and the global PrEP market. As the largest PrEP market in the world, South Africa’s leadership can help drive the demand, volume, market confidence and lower prices needed to accelerate equitable access across the continent and the world.
